Compare CRSP & SON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | SON |
|---|---|---|
| Founded | 2013 | 1899 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Containers/Packaging |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.4B |
| IPO Year | 2016 | 2014 |
| Metric | CRSP | SON |
|---|---|---|
| Price | $55.44 | $48.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 11 |
| Target Price | ★ $87.56 | $62.89 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 11-09-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 4.42% |
| EPS Growth | N/A | ★ 510.30 |
| EPS | N/A | ★ 0.68 |
| Revenue | $289,590,000.00 | ★ $7,518,753,000.00 |
| Revenue This Year | $1,063.30 | N/A |
| Revenue Next Year | $283.48 | $1.94 |
| P/E Ratio | ★ N/A | $72.99 |
| Revenue Growth | ★ 9169.85 | 41.72 |
| 52 Week Low | $44.12 | $38.65 |
| 52 Week High | $78.48 | $60.67 |
| Indicator | CRSP | SON |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 30.63 |
| Support Level | $50.56 | $46.74 |
| Resistance Level | $60.04 | $49.38 |
| Average True Range (ATR) | 2.83 | 1.05 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 51.06 | 0.15 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.